EYPT

EyePoint, Inc. Common Stock (EYPT) | Rumor.io

EyePoint

EYPT

Attention (50-day avg)0%

Attention rank (50-day avg)#688

Bullish sentiment (50-day avg)44%

Price to earnings ratio-1.04

Market capitalization277.5M

Earnings per share-3.75

Dividend yield (TTM)—

Revenue (annual)31.4M

Net income (annual)-232M

Social

What share of all stock conversation is about EYPT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% +0

Sep 28

The company's market potential is being compared to that of KOD, with the Lucia trial results seen as a key factor in EYPT's future success.
Some investors are confident in the company's prospects, citing the solid Duravyu program and the potential for a positive outcome from the Lucia trial.
The current market price of EYPT is considered absurdly low compared to its liquid assets, with some investors hoping for a significant price increase.

Generated by AI

Sentiment

Of the messages about EYPT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% +52.63	43.24% +39.24	44.67% +0.62	63.11% -22.76
Bearish	0% -52.63	56.76% -39.24	55.33% -0.62	36.89% +22.76

Bullish· Aug 18

The company's director, Karen Zaderej, has shown significant confidence in the stock by buying 10,600 shares, increasing her direct position by 27.5% to 49,100 shares.
Retail sentiment remains extremely bullish, with 90% of investors optimistic about the stock's future performance, indicating a strong trend upward towards the company's second phase III clinical trial results in Q4.
The stock's price is considered "stupid cheap" by investors, suggesting that the current price is undervalued and may rise to at least $7-$7.5 in the near future.

Bearish· Aug 21

The company's recent clinical trial failure is likely to have a significant impact on its future, with many analysts downgrading their ratings and adjusting their target prices downward.
The stock's price has been heavily affected by the trial failure, with some analysts predicting it will drop even further, and the company's current situation is being compared to another failed biotech stock.
The stock's performance is being driven by short selling and selling pressure, with many investors predicting a continued decline in the stock's price, and some even predicting it will drop below $4.

Generated by AI

Topics

Of the messages about EYPT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	100%	91.67%	36.62%
Announcements	—	0%	0%	30.55%
Controversies	—	0%	0%	0.99%
Technical Analysis	—	0%	8.33%	3.15%
Earnings	—	0%	0%	14.64%
Macro	—	0%	0%	14.05%

Announcements· Oct 15

EyePoint Pharmaceuticals ($EYPT) announced the pricing of an underwritten public offering of 11 million shares of its common stock at $12.00 per share, raising approximately $150 million in gross proceeds.
The company has begun pivotal Phase 3 trials for DURAVYU, a treatment for diabetic macular edema, with first patient dosing anticipated in early 2026.
DURAVYU is a dual-acting therapy that targets both VEGF and IL-6 pathways, aiming for 6-month durability and reduced treatment burden in diabetic macular edema.

Controversies· Mar 21

EyePoint Pharmaceuticals, Inc. (EYPT) has filed a lawsuit against Ocular Therapeutix (OCUL) alleging false or misleading statements about EYPT's experimental eye drug.
The lawsuit, filed in Massachusetts court, claims that OCUL's statements caused EyePoint's CEO to have a hard-on for Ocular and their CEO, and that the company's management was reckless in presenting Voronalib safety data unassociated with Duravyu.
The controversy has the potential to generate volatility and significant options flow, and may lead to a change in momentum in the sector.

Technical Analysis· Nov 17

$EYPT is showing a potential move higher, with a possible breakout to $19 or $19.50.
The stock is consolidating and may be setting up for a squeeze, with a coil pattern forming and a possible rejection at $17.5.
$EYPT has shown a bullish trend, with a bounce from VWAP and a possible move to $21 if the stock holds at $18.

Generated by AI

Community

Of the messages about EYPT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	43.16%	35.99%	27.9%
Newcomers	0%	56.84%	64.01%	72.1%

Regulars· Sep 15

The market may have misinterpreted the LUGANO trial results, which could lead to a reevaluation of DURAVYU's potential as a next-generation wet-AMD therapy.
The LUCIA trial's success could lead to a shift in focus from whether DURAVYU can replace Eylea to which program can actually survive a full-strength Eylea comparison.
The company's management may be signaling a non-dilutive partnership, and a successful LUCIA trial could lead to a reevaluation of the stock's value, with some analysts predicting a potential rise in the share price.

Newcomers· Sep 15

Many newcomers are focused on trying to understand the recent selloff in $EYPT, with some questioning the market's negative reaction to the company's routine investor presentation.
Others are looking for signs of a reversal, with some pointing to the stock's recent price action and the potential for a double bottom formation if it closes up on big volume.
Some users are also sharing their personal experiences with the stock, including stories of buying in at low prices and getting greedy, as well as warnings to be careful and not to be blind to the stock's potential.

Generated by AI

News

JonesTrading Sticks to Its Buy Rating for EyePoint Pharmaceuticals (EYPT)

Detailed price information for Eyepoint Inc (EYPT-Q) from The Globe and Mail including charting and trades.

1d agoThe Globe and Mail

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

WATERTOWN, Mass., Sept. 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employee as inducement award outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 3,00

14d agoYahoo Finance

EyePoint at Morgan Stanley conference: duravyu path stays open

15d agoInvesting.com

Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO), EyePoint Pharmaceuticals (EYPT) and Abbott Laboratories (ABT)

Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.

19d agoThe Globe and Mail

EyePoint at Cantor conference: mixed trial data leaves key catalyst ahead

19d agoInvesting.com

EyePoint at Citi summit: wet AMD setback, but path stays open

20d agoInvesting.com

Also Discussed

Investors talking about EYPT also mention

#	Name	Attention
1	Ocular Therapeutix, Inc.OCUL	0.02%-0.04
2	Clearside Biomedical Inc.CLSD	0%0
3	vTv Therapeutics Inc. Class A Common StockVTVT	0%new
4	4D Molecular Therapeutics, Inc.FDMT	0%new
5	ALIM - Alimera Sciences, Inc.	——
6	Kodiak Sciences Inc.KOD	0.07%-0.17
7	Verastem Inc.VSTM	0%0
8	Regenxbio Inc.RGNX	0%+0
9	Aura Biosciences, Inc.AURA	0%0
10	Alcon Inc.ALC	0%0

EyePoint, Inc. Common Stock

Healthcare
Biotechnology

EyePoint, Inc. Common Stock represents equity in EyePoint, Inc., a biopharmaceutical company focused on developing and commercializing therapies for serious retinal diseases. The company’s current portfolio centers on ophthalmology products and sustained-release drug delivery technologies designed to treat eye disorders and improve the management of retinal conditions. Its marketed and development-stage programs address areas such as retinal vascular disease, diabetic macular edema, and other eye diseases, using proprietary platforms that support localized, long-acting treatment delivery. EyePoint, Inc. serves the specialized eye-care market, working with healthcare providers and the broader ophthalmic industry through products and pipeline assets that target chronic retinal conditions. Headquartered in Watertown, Massachusetts, the company is positioned within the life sciences sector as a developer of therapies and drug-delivery systems for ophthalmic use.

Website

Location

480 Pleasant Street

Watertown, MA, 02472

United States

Social

What share of all stock conversation is about EYPT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% +0

Sep 28

The company's market potential is being compared to that of KOD, with the Lucia trial results seen as a key factor in EYPT's future success.
Some investors are confident in the company's prospects, citing the solid Duravyu program and the potential for a positive outcome from the Lucia trial.
The current market price of EYPT is considered absurdly low compared to its liquid assets, with some investors hoping for a significant price increase.

Generated by AI

Sentiment

Of the messages about EYPT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% +52.63	43.24% +39.24	44.67% +0.62	63.11% -22.76
Bearish	0% -52.63	56.76% -39.24	55.33% -0.62	36.89% +22.76

Bullish· Aug 18

The company's director, Karen Zaderej, has shown significant confidence in the stock by buying 10,600 shares, increasing her direct position by 27.5% to 49,100 shares.
Retail sentiment remains extremely bullish, with 90% of investors optimistic about the stock's future performance, indicating a strong trend upward towards the company's second phase III clinical trial results in Q4.
The stock's price is considered "stupid cheap" by investors, suggesting that the current price is undervalued and may rise to at least $7-$7.5 in the near future.

Bearish· Aug 21

The company's recent clinical trial failure is likely to have a significant impact on its future, with many analysts downgrading their ratings and adjusting their target prices downward.
The stock's price has been heavily affected by the trial failure, with some analysts predicting it will drop even further, and the company's current situation is being compared to another failed biotech stock.
The stock's performance is being driven by short selling and selling pressure, with many investors predicting a continued decline in the stock's price, and some even predicting it will drop below $4.

Generated by AI

Topics

Of the messages about EYPT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	100%	91.67%	36.62%
Announcements	—	0%	0%	30.55%
Controversies	—	0%	0%	0.99%
Technical Analysis	—	0%	8.33%	3.15%
Earnings	—	0%	0%	14.64%
Macro	—	0%	0%	14.05%

Announcements· Oct 15

EyePoint Pharmaceuticals ($EYPT) announced the pricing of an underwritten public offering of 11 million shares of its common stock at $12.00 per share, raising approximately $150 million in gross proceeds.
The company has begun pivotal Phase 3 trials for DURAVYU, a treatment for diabetic macular edema, with first patient dosing anticipated in early 2026.
DURAVYU is a dual-acting therapy that targets both VEGF and IL-6 pathways, aiming for 6-month durability and reduced treatment burden in diabetic macular edema.

Controversies· Mar 21

EyePoint Pharmaceuticals, Inc. (EYPT) has filed a lawsuit against Ocular Therapeutix (OCUL) alleging false or misleading statements about EYPT's experimental eye drug.
The lawsuit, filed in Massachusetts court, claims that OCUL's statements caused EyePoint's CEO to have a hard-on for Ocular and their CEO, and that the company's management was reckless in presenting Voronalib safety data unassociated with Duravyu.
The controversy has the potential to generate volatility and significant options flow, and may lead to a change in momentum in the sector.

Technical Analysis· Nov 17

$EYPT is showing a potential move higher, with a possible breakout to $19 or $19.50.
The stock is consolidating and may be setting up for a squeeze, with a coil pattern forming and a possible rejection at $17.5.
$EYPT has shown a bullish trend, with a bounce from VWAP and a possible move to $21 if the stock holds at $18.

Generated by AI

Community

Of the messages about EYPT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	43.16%	35.99%	27.9%
Newcomers	0%	56.84%	64.01%	72.1%

Regulars· Sep 15

The market may have misinterpreted the LUGANO trial results, which could lead to a reevaluation of DURAVYU's potential as a next-generation wet-AMD therapy.
The LUCIA trial's success could lead to a shift in focus from whether DURAVYU can replace Eylea to which program can actually survive a full-strength Eylea comparison.
The company's management may be signaling a non-dilutive partnership, and a successful LUCIA trial could lead to a reevaluation of the stock's value, with some analysts predicting a potential rise in the share price.

Newcomers· Sep 15

Many newcomers are focused on trying to understand the recent selloff in $EYPT, with some questioning the market's negative reaction to the company's routine investor presentation.
Others are looking for signs of a reversal, with some pointing to the stock's recent price action and the potential for a double bottom formation if it closes up on big volume.
Some users are also sharing their personal experiences with the stock, including stories of buying in at low prices and getting greedy, as well as warnings to be careful and not to be blind to the stock's potential.

Generated by AI

EyePoint

Social

Sep 28

Bullish· Aug 18

Bearish· Aug 21

Announcements· Oct 15

Controversies· Mar 21

Technical Analysis· Nov 17

Regulars· Sep 15

Newcomers· Sep 15

JonesTrading Sticks to Its Buy Rating for EyePoint Pharmaceuticals (EYPT)

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

EyePoint at Morgan Stanley conference: duravyu path stays open

Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO), EyePoint Pharmaceuticals (EYPT) and Abbott Laboratories (ABT)

EyePoint at Cantor conference: mixed trial data leaves key catalyst ahead

EyePoint at Citi summit: wet AMD setback, but path stays open

Also Discussed

EyePoint, Inc. Common Stock

Company Information

Location

JonesTrading Sticks to Its Buy Rating for EyePoint Pharmaceuticals (EYPT)

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

EyePoint at Morgan Stanley conference: duravyu path stays open

Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO), EyePoint Pharmaceuticals (EYPT) and Abbott Laboratories (ABT)

EyePoint at Cantor conference: mixed trial data leaves key catalyst ahead

EyePoint at Citi summit: wet AMD setback, but path stays open

Also Discussed

Social

Sep 28

Bullish· Aug 18

Bearish· Aug 21

Announcements· Oct 15

Controversies· Mar 21

Technical Analysis· Nov 17

Regulars· Sep 15

Newcomers· Sep 15